DBV TECHNOLOGIE/S (DBVT) Downgraded by BidaskClub

BidaskClub downgraded shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) from a hold rating to a sell rating in a research note released on Tuesday, BidAskClub reports.

Several other equities research analysts have also commented on the stock. Stifel Nicolaus reaffirmed a hold rating and issued a $10.00 price target on shares of DBV TECHNOLOGIE/S in a report on Wednesday, March 6th. JMP Securities reaffirmed a buy rating and issued a $20.00 price target on shares of DBV TECHNOLOGIE/S in a report on Wednesday, March 6th. Finally, Zacks Investment Research lowered shares of DBV TECHNOLOGIE/S from a buy rating to a hold rating in a report on Friday, April 12th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $14.91.

NASDAQ:DBVT opened at $8.99 on Tuesday. DBV TECHNOLOGIE/S has a one year low of $3.60 and a one year high of $25.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.30 and a current ratio of 3.34.

A number of large investors have recently bought and sold shares of the business. First Midwest Bank Trust Division boosted its stake in shares of DBV TECHNOLOGIE/S by 505.4% during the 4th quarter. First Midwest Bank Trust Division now owns 988,891 shares of the company’s stock worth $6,349,000 after acquiring an additional 825,533 shares in the last quarter. OLD Mission Capital LLC boosted its stake in shares of DBV TECHNOLOGIE/S by 1,278.6% during the 4th quarter. OLD Mission Capital LLC now owns 143,338 shares of the company’s stock worth $920,000 after acquiring an additional 132,941 shares in the last quarter. Bailard Inc. purchased a new stake in shares of DBV TECHNOLOGIE/S during the 1st quarter worth about $2,675,000. Bank of New York Mellon Corp boosted its stake in shares of DBV TECHNOLOGIE/S by 334.1% during the 4th quarter. Bank of New York Mellon Corp now owns 1,645,000 shares of the company’s stock worth $10,561,000 after acquiring an additional 1,266,041 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of DBV TECHNOLOGIE/S by 0.9% during the 3rd quarter. BlackRock Inc. now owns 312,261 shares of the company’s stock worth $7,014,000 after acquiring an additional 2,741 shares in the last quarter. 44.02% of the stock is currently owned by institutional investors.

About DBV TECHNOLOGIE/S

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Further Reading: What is a Derivative?

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.